November 2018 P & T Updates

Size: px
Start display at page:

Download "November 2018 P & T Updates"

Transcription

1 November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY ml per 90 days COLCHICINE CAPSULES Alternatives propranolol, propranolol ER, oral timolol, divalproex DR, atenolol, nadolol, Ajovy*, Emgality* propranolol, propranolol ER, oral timolol, divalproex DR, atenolol, nadolol, Aimovig*, Emgality* 1 No 1 No 3 capsules per day colchicine tablets COPIKTRA tablets per day, 30 day DELSTRIGO 2 No 2 No 1 tablet per day Depending on your specific benefits and in which state you reside, some drugs on this list may have no cost sharing. Imbruvica*, Venclexta*, Zydelig* Complera, Odefsey, Atripla, Symfi, Symfi Lo DOPTELET 3 2 Platelet Count 40,000 to < 50,000 x 10 9 /L: 10 tablets per fill Platelet Count < 40,000 x 10 9 /L: 15 tablets per fill none EMGALITY ml per 30 days EPIDIOLEX 3 No 2 No - FULPHILA 3 2 LYRICA CR OLUMIANT 3 2 ORILISSA dose per chemotherapy cycle 82.5 &165 mg: 3 tablets per day 330 mg: 2 tablets per day 1 tablet per day, 30 day 150 mg: 1 tablet per day, 30 day supply per fill 200 mg tablet: 2 tablets per day, 30 day propranolol, propranolol ER, oral timolol, divalproex DR, atenolol, nadolol, Aimovig*, Ajovy* felbamate, lamotrigine, topiramate, valproic acid, divalproex, clonazepam, zonisamide, levetiracetam Neupogen*, Neulasta* Diabetic Peripheral Neuropathy: duloxetine, Lyrica Postherpetic Neuralgia: gabapentin, Lyrica Humira* norethindrone acetate, danazol capsule, formulary oral NSAIDS, Synarel

2 Commercial (cont.) Triple Tier 4th Tier Applicable Traditional Prior Auth Detailed s Depending on your specific benefits and in which state you reside, some drugs on this list may have no cost sharing. Alternatives PALYNZIQ mg/0.5 ml syringe: 0.15 ml per day 10 mg/0.5 ml syringe: 0.5 ml per day 20 mg/ml syringe: 2 ml per day Kuvan* PIFELTRO 2 No 2 No 2 tablets per day efavirenz, nevirapine, Edurant, Rescriptor, Intelence RETACRIT 3 2 No - Epogen*, Procrit*, Aranesp* SUBOXONE FILM 3 No 2 No 2/0.5 mg: 3 films per day 4/1 mg & 8/2 mg: 2 films per day 12/3 mg: 1 film per day SYMTUZA 2 No 2 No 1 tablet per day VIZIMPRO tablet per day, 30 day buprenorphine, buprenorphine/naloxone Genvoya, Stribild, Complera, Odefsey, Triumeq, Biktarvy, Atripla, Symfi, Symfi Lo Gilotrif*, Iressa*, Tagrisso*, Tarceva* MANDATORY GENERIC Commercial plan members all members not on a Geisinger Gold, GHP Marketplace, GHP Family or GHP Kids plan will no longer be able to obtain brand name drugs when a generic is available without prior authorization. Ongoing therapy will not be disrupted and narrow therapeutic agents will remain available. HEPATITIS C CENTER OF EXCELLENCE Beginning on 1/1/19, members seeking treatment for hepatitis C virus (HCV) will be required to receive their hepatitis C antiviral medications (GHP pharmacy prior authorization required) from a Center of Excellence (COE) provider following an office appointment and recommendations.

3 CHIP Tier Prior Auth AIMOVIG 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY ml per 90 days COLCHICINE CAPSULES Alternatives timolol, divalproex DR, divalproex ER, topiramate, amitriptyline, venlafaxine, atenolol, nadolol, Ajovy*, Emgality* timolol, divalproex DR, divalproex ER, topiramate, amitriptyline, venlafaxine, atenolol, nadolol, Aimovig*, Emgality* 2 No 3 capsules per day colchicine tablets COPIKTRA 0 2 tablets per day, 30 day DELSTRIGO 2 No 1 tablet per day DOPTELET 2 Platelet Count 40,000 to < 50,000 x 10 9 /L: 10 tablets per fill Platelet Count < 40,000 x 10 9 /L: 15 tablets per fill EMGALITY 2 1 ml per 30 days EPIDIOLEX 2 No - FULPHILA 2 LYRICA CR - OLUMIANT 2 1 dose per chemotherapy cycle 82.5 &165 mg: 3 tablets per day 330 mg: 2 tablets per day 1 tablet per day, 30 day Imbruvica*, Venclexta*, Zydelig* Complera, Odefsey, Atripla, Symfi, Symfi Lo none timolol, divalproex DR, divalproex ER, topiramate, amitriptyline, venlafaxine, atenolol, nadolol, Aimovig*, Ajovy* felbamate, lamotrigine, topiramate, valproic acid, divalproex, clonazepam, zonisamide, levetiracetam Neupogen*, Neulasta* Diabetic Peripheral Neuropathy: duloxetine, Lyrica Postherpetic Neuralgia: gabapentin, Lyrica Humira* ORILISSA 2 PALYNZIQ mg: 1 tablet per day, 30 day 200 mg tablet: 2 tablets per day, 30 day 2.5 mg/0.5 ml syringe: 0.15 ml per day 10 mg/0.5 ml syringe: 0.5 ml per day 20 mg/ml syringe: 2 ml per day norethindrone acetate, danazol capsule, formulary oral NSAIDS, Synarel Kuvan*

4 CHIP (cont.) Tier Prior Auth Detailed s Alternatives PIFELTRO 2 No 2 tablets per day efavirenz, nevirapine, Edurant, Rescriptor, Intelence RETACRIT 2 No - Epogen*, Procrit*, Aranesp* SUBOXONE FILM 2 No 2/0.5 mg: 3 films per day 4/1 mg & 8/2 mg: 2 films per day 12/3 mg: 1 film per day SYMTUZA 2 No 1 tablet per day VIZIMPRO 0 HEPATITIS C CENTER OF EXCELLENCE 1 tablet per day, 30 day buprenorphine, buprenorphine/naloxone Genvoya, Stribild, Complera, Odefsey, Triumeq, Biktarvy, Atripla, Symfi, Symfi Lo Gilotrif*, Iressa*, Tagrisso*, Tarceva* Beginning on 1/1/19, members seeking treatment for hepatitis C virus (HCV) will be required to receive their hepatitis C antiviral medications (GHP pharmacy prior authorization required) from a Center of Excellence (COE) provider following an office appointment and recommendations.

5 GHP Family AJOVY GHP Family Tier Prior Auth Detailed s 4.5 ml per 90 days Alternative(s) propranolol, propranolol ER, timolol, divalproex DR, divalproex ER, topiramate ER*, topiramate, atenolol, nadolol BECONASE AQ Brand No - Mometasone COLCHICINE CAPSULES Generic No 3 capsules daily Colchicine tablets COPIKTRA Brand 60 tablets per 30 days Imbruvica*, Venclexta*, Rituxan IV*, Rituxan Hycela* DELSTRIGO Brand No 1 tablet daily Complera, Odefsey, Atripla, Symfi, Symfi Lo For platelet count 40,000 to <50,000 x 109/L 10 DOPTELET tablets per fill, for platelet count <40,000 x 109/L 15 tablets per fill. One fill per Rx. - EMGALITY 1 ml per 30 days EPIDIOLEX Brand No - propranolol, propranolol ER, timolol, divalproex DR, divalproex ER, topiramate ER*, topiramate, atenolol, nadolol felbamate, lamotrigine, topiramate, topiramate ER*, valproic acid, divalproex, clonazepam, zonisamide, levetiracetam, Banzel* One 6mg dose per FULPHILA Generic Neupogen*, Neulasta* chemotherapy cycle IRESSA Brand 30 tablets per 30 days Gilotrif*, Tarceva*, Vizimpro* 82.5 mg tablets,165 mg duloxetine, gabapentin, lidocaine tablets: 3 tablets daily; LYRICA CR patch* 330 mg tablets: 2 tablets Lyrica* daily OLUMIANT ORILISSA Brand 1 tablet daily 150 mg: 30 tablets per 30 days; 200 mg: 60 tablets per 30 days Cimzia*, Enbrel*, Humira*, Kineret*, Orencia* Medroxyprogesterone IM 150 mg/ml, norethindrone acetate, danazol capsule, celecoxib, choline magnesium salicylate, diclofenac, diflunisal, etodolac, etodolac extended release, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meloxicam

6 GHP Family (cont.) GHP Family Tier Prior Auth Detailed s Alternative(s) PALYNZIQ Brand 2.5 mg/0.5 ml syringe: 0.15 ml per day; 10 mg/0.5 ml syringe: 0.5 ml per day; Kuvan* 20 mg/ml syringe: 2 ml per day PIFELTRO Brand No 2 tablets per day Efavirenz, Nevirapine Edurant, Rescriptor, Intelence RETACRIT Brand No - Epogen*, Procrit*, Aranesp* SUBOXONE FILM Brand No 2/0.5 mg 3 daily, 4/1 mg, 8/2 mg 2 daily, 12/3 mg 1 daily SYMTUZA Brand 1 tablet daily Buprenorphine SL tablets, Buprenorphine/Naloxone SL tablets Genvoya, Stribild, Complera, Odefsey, Triumeq, Biktarvy, Atripla, Symfi, Symfi Lo VIZIMPRO Brand 30 tablets per 30 days Gilotrif*, Tagrisso*, Tarceva*

7 Geisinger Gold AJOVY $0 Deductible Brand Preferred COPIKTRA Specialty DELSTRIGO Specialty DOPTELET Specialty EMGALITY EPIDIOLEX Brand Preferred Brand Preferred FULPHILA Specialty Standard Prior Auth Detailed s 1.5 ml/30 days 60 tablets/30 days No 1 tablet/day 40 mg/day dose (10 count pack) 10 tablets/30 days; 60 mg/day dose (15 count pack) 15 tablets/30 days 2 ml/30 days No - No - Alternative(s) metoprolol, propranolol, timolol, atenolol, nadolol, topiramate, divalproex, sodium valproate, amitriptyline*, venlafaxine Venclexta*, Imbruvica*, Zydelig*, Rituxan*, Aliqopa* Complera, Odefsey, Atripla, Symfi, Symfi Lo none metoprolol, propranolol, timolol, atenolol, nadolol, topiramate, divalproex, sodium valproate, amitriptyline*, venlafaxine Felbamate, lamotrigine, topiramate, topiramate ER*, clonazepam, levetiracetam, Banzel*, Lamictal, Onfi* Granix*, Neupogen*, Neulasta* LIBTAYO Specialty No - Cisplatin, Gilotrif*, Tarceva*, Tykerb*, Vectibix*, Erbitux, Keytruda*, Opdivo*, Yervoy* LYRICA CR Brand Preferred OLUMIANT Specialty ORILISSA Specialty 82.5 mg tablets: 3 tablets per day; 165 mg tablets: 3 tablets per day; 330 mg tablets: 2 tablets per day 1 tablet/day 150 mg: 30 tablets/30 days; 200 mg: 60 tablets/30 days Lyrica, duloxetine, gabapentin, lidocaine patch* azathioprine, cyclosporine, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, Depen, Ridaura, Humira*, Xeljanz* celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, norethindrone acetate, danazol, Zoladex, Synarel, Lupron Depot

8 Geisinger Gold (cont.) $0 Deductible PALYNZIQ Specialty PIFELTRO Specialty POTELIGEO Specialty RETACRIT Brand Preferred SYMTUZA Specialty VIZIMPRO Specialty Standard Prior Auth Detailed s 2.5 mg syringe: 4.5 ml/30 days; 10 mg syringe: 15 ml/30 days; 20 mg syringe: 60 ml/30 days No 2 tablets/day Alternative(s) Kuvan* Efavirenz, Nevirapine,Rescriptor, Intelence, Edurant - Zolinza* 12 ml/28 days No 1 tablet/day 1 tablet/day Epogen*, Procrit*, Aranesp*, Mircera* Genvoya, Stribild, Complera, Odefsey, Triumeq, Biktarvy, Atripla, Symfi, Symfi Lo Gilotrif*, Iressa*, Tagrisso*, Tarceva*

9 Marketplace Tier Prior Auth AIMOVIG 5 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY ml per 90 days COLCHICINE CAPSULES Alternatives timolol, divalproex DR, atenolol, nadolol, Ajovy*, Emgality* timolol, divalproex DR, atenolol, nadolol, Aimovig*, Emgality* 2 No 3 capsules per day colchicine tablets COPIKTRA 0 2 tablets per day, 30 day DELSTRIGO 3 No 1 tablet per day DOPTELET 5 Platelet Count 40,000 to < 50,000 x 10 9 /L: 10 tablets per fill Platelet Count < 40,000 x 10 9 /L: 15 tablets per fill EMGALITY 5 1 ml per 30 days EPIDIOLEX 4 No - FULPHILA 5 LYRICA CR - OLUMIANT 5 1 dose per chemotherapy cycle 82.5 &165 mg: 3 tablets per day 330 mg: 2 tablets per day 1 tablet per day, 30 day Imbruvica*, Venclexta*, Zydelig* Complera, Odefsey, Atripla, Symfi, Symfi Lo none timolol, divalproex DR, atenolol, nadolol, Aimovig*, Ajovy* felbamate, lamotrigine, topiramate, valproic acid, divalproex, clonazepam, zonisamide, levetiracetam Neupogen*, Neulasta* Diabetic Peripheral Neuropathy: duloxetine, Lyrica Postherpetic Neuralgia: gabapentin, Lyrica Humira* ORILISSA mg: 1 tablet per day, 30 day 200 mg tablet: 2 tablets per day, 30 day supply per fill norethindrone acetate, danazol capsule, formulary oral NSAIDS, Synarel

10 Marketplace (cont.) Tier Prior Auth Detailed s Alternatives PALYNZIQ mg/0.5 ml syringe: 0.15 ml per day 10 mg/0.5 ml syringe: 0.5 ml per day Kuvan* 20 mg/ml syringe: 2 ml per day PIFELTRO 3 No 2 tablets per day efavirenz, nevirapine, Edurant, Rescriptor, Intelence RETACRIT 5 No - Epogen*, Procrit*, Aranesp* SUBOXONE FILM 2 No 2/0.5 mg: 3 films per day 4/1 mg & 8/2 mg: 2 films per day 12/3 mg: 1 film per day buprenorphine, buprenorphine/naloxone SYMTUZA 3 No 1 tablet per day VIZIMPRO 0 HEPATITIS C CENTER OF EXCELLENCE 1 tablet per day, 30 day Genvoya, Stribild, Complera, Odefsey, Triumeq, Biktarvy, Atripla, Symfi, Symfi Lo Gilotrif*, Iressa*, Tagrisso*, Tarceva* Beginning on 1/1/19, members seeking treatment for hepatitis C virus (HCV) will be required to receive their hepatitis C antiviral medications (GHP pharmacy prior authorization required) from a Center of Excellence (COE) provider following an office appointment and recommendations.

May 2016 P & T Updates

May 2016 P & T Updates Commercial Triple Tier 4th Tier Applicabl e Traditional Detailed s 2 films - DESCOVY 2 2 1 tablet NARCAN 2 2 ODEFSEY 2 2 1 tablet REPATHA 2 2 HoFH: 3 ml per 28 ROSUVASTATIN 1 1 - UPTRAVI 3 2 - Alternatives

More information

May 2017 P&T Updates

May 2017 P&T Updates May 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives 6 ml per AMPYRA 3 2 2 tablets per day, 30 day BYDUREON 3 2 4 vials per 28 days 5 mcg pen: 1.2 ml per

More information

January 2018 P & T Updates

January 2018 P & T Updates January 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional BEVYXXA 3 No 2 BOSULIF 3 2 * Indicates prior authorization (PA) or step (ST) Depending on your specific benefits and in

More information

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015) WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015) **To get updated information about the drugs covered by WellCare/ Ohana, please visit our website (https://www.wellcare.com

More information

March 2017 P&T Updates

March 2017 P&T Updates March 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth DICLEGIS 3 No 2 No Yes EMVERM 2 No 2 Yes Yes Detailed s 4 tablets per day, 9 month supply per year Pinworms: 1 tablet

More information

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

Ambetter 90-Day-Supply Maintenance Drug List

Ambetter 90-Day-Supply Maintenance Drug List Ambetter 90-Day-Supply Maintenance Drug List What is the Ambetter 90-Day-Supply Maintenance Drug List? Ambetter 90-Day-Supply Maintenance Drug List is a list of maintenance medications that are available

More information

2018 WPS MedicareRx Plan (PDP) Step Therapy

2018 WPS MedicareRx Plan (PDP) Step Therapy 2018 WPS MedicareRx Plan (PDP) Step Therapy In some cases, the WPS MedicareRx Plan (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that

More information

July 2017 P&T Updates

July 2017 P&T Updates July 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives ALUNBRIG 3 2 DUPIXENT Pharmacy 3 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per

More information

March 2018 P & T Updates

March 2018 P & T Updates March 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AURYXIA 3 2 12 tablets per BAXDELA TABLETS 3 2 2 tablets per Depending on your specific benefits and in which

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

2018 CareOregon Advantage Part D Formulary Changes

2018 CareOregon Advantage Part D Formulary Changes 2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD

More information

Formulary (Drug List)

Formulary (Drug List) Formulary (Drug List) PacificSource Community Solutions This list was updated on /5/07 Please Read: This document contains information about the drugs we cover on this plan. For a complete, up-to-date

More information

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details. FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization

More information

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors)

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors) Table S1. Medications categorized as s all (Warner-Schmidt) includes all (s, Salicytes, and Cox-2 inhibitors) Nonsteroidal anti-inflammatory agents Bromfenac Diclofenac Diclofenac-misoprostol Etodolac

More information

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ASEBP and ARTA TARP Drugs and Reference Price by Categories ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice MEDICAID PROVIDER BULLETIN March 2019 Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at the fourth quarter pharmacy and therapeutics

More information

Available Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over

Available Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)

More information

Insulin Class Updates. SGLT2 Inhibitor Class Updates

Insulin Class Updates. SGLT2 Inhibitor Class Updates SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE DECEMBER 2018 ISSUE 4 HELPFUL NUMBERS FOR PROVIDERS CVS: 1-888-512-8935 Primary: 004336 Secondary Commercial: 013089 Secondary

More information

Neighborhood Medicaid Formulary Changes: June 2017

Neighborhood Medicaid Formulary Changes: June 2017 Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were

More information

NSAIDs. NSAIDs are important but they can have side effects.

NSAIDs. NSAIDs are important but they can have side effects. NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such

More information

HAQ-II(Health Assessment Questionnaire-II)

HAQ-II(Health Assessment Questionnaire-II) Kathy Karamlou, MD 355 Placentia Ave, suite 208 Newport Beach, CA 92663 949-631-6500 949-631-9700 NAME: DATE: DOB: HAQ-II(Health Assessment Questionnaire-II) We are interested in learning how your illness

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Alaska Medicaid 90 Day** Generic Prescription Medication List

Alaska Medicaid 90 Day** Generic Prescription Medication List 1 ACYCLOVIR 200 MG CAPSULE BUPROPION HCL 150 MG TAB ER 24H ACYCLOVIR 200 MG/5ML BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 400 MG TABLET BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 800 MG TABLET BUPROPION HCL

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date: Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

September 2018 Pharmacy & Therapeutics Committee Decisions

September 2018 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare (approved drug list). These changes are reviewed based

More information

10 Musculoskeletal and Joint Diseases

10 Musculoskeletal and Joint Diseases 10 Musculoskeletal and Joint Diseases To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and British Society of Rheumatology guidelines and guidance

More information

2016 Formulary (List of Covered Drugs) SUPERIOR HEALTH PLAN, INC. Superior HealthPlan Advantage (HMO SNP)

2016 Formulary (List of Covered Drugs) SUPERIOR HEALTH PLAN, INC. Superior HealthPlan Advantage (HMO SNP) SUPERIOR HEALTH PLAN, INC. Superior HealthPlan Advantage (HMO SNP) 2016 Formulary (List of Covered s) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. 00016423, Version

More information

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $ MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

Introduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis

Introduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If

More information

Pharmacy and Therapeutics (P&T) Committee Provider Update

Pharmacy and Therapeutics (P&T) Committee Provider Update Pharmacy and Therapeutics (P&T) Committee Provider Update THIRD QUARTER 2018 P&T Committee Decisions Effective September 1, 2018 Dear Healthcare Practitioner: The Presbyterian Health Plan, Inc., and Presbyterian

More information

2017 Formulary (List of Covered Drugs)

2017 Formulary (List of Covered Drugs) 017 Formulary (List of Covered Drugs) Liberty Health Advantage Preferred Choice (HMO) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File

More information

Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report

More information

Birthdate: / / Address: Age: Sex: M F. Telephone: H ( ) City State Zip W ( ) C ( )

Birthdate: / / Address: Age: Sex: M F. Telephone: H ( ) City State Zip W ( ) C ( ) Please complete this questionnaire in its entirety, even if you feel some questions may not apply to you. Our staff is available should you have any questions, or need assistance with the completion of

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

Lost in Translation: Making Sense of Clinical Treatment Guidelines

Lost in Translation: Making Sense of Clinical Treatment Guidelines Lost in Translation: Making Sense of Clinical Treatment Guidelines Charles E. Argoff, MD, CPE Disclosures: Charles Argoff Financial Disclosure: Consultant: Teva, Daiichi Sakyo, Pfizer, Nektar, Purdue,

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Health Partners Medicare Prime 2019 Formulary Changes

Health Partners Medicare Prime 2019 Formulary Changes Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes

More information

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Information for Vermont Prescribers of Prescription Drugs

Information for Vermont Prescribers of Prescription Drugs Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same

More information

2016 List of Covered Drugs (Formulary)

2016 List of Covered Drugs (Formulary) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. FOR RE INFORMATION, call Member Services at 1-8 from 8 a.m. to 8 p.m., seven days a week. TTY rs call 711. On weekends

More information

Regence MedAdvantage + Rx Classic (PPO) and. Regence MedAdvantage + Rx Enhanced (PPO) 2015 Formulary. (List of Covered Drugs)

Regence MedAdvantage + Rx Classic (PPO) and. Regence MedAdvantage + Rx Enhanced (PPO) 2015 Formulary. (List of Covered Drugs) Regence MedAdvantage + Rx Classic (PPO) and Regence MedAdvantage + Rx Enhanced (PPO) 2015 Formulary (List of Covered s) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT SOME OF THE DRUGS WE COVER

More information

New Patient History Form Today s Date:

New Patient History Form Today s Date: New Patient History Form Today s Date: MICHAEL L. MAWBY, MD MARIANNE PEACOCK, CNP 1115 S. Union Street Traverse City, MI 49684 Form Revised 1/18/2016 Name: Birthdate: (Last) (First) (MI) (Maiden) (MM/DD/YYYY)

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy

More information

Anticonvulsant Prior Authorization Request

Anticonvulsant Prior Authorization Request Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial

More information

Patient History Form

Patient History Form Patient History Form of first appointment: / / Time of appointment: Cell Phone: MONTH DA Y YEAR Name: Birthdate: / / LAST FIRST MIDDLE INITIAL MAIDEN MONTH DAY YEAR Address: Age: Sex: F M STREET APT# CITY

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

Memorial Hermann Advantage HMO February 2019 Formulary Addendum Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added

More information

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations

More information

in this web service Cambridge University Press

in this web service Cambridge University Press Prescriber's Guide in this web service in this web service Essential Pain Pharmacology The Prescriber's Guide Howard S. Smith Professor of Anesthesiology, Internal Medicine, Physical Medicine and Rehabilitation,

More information

Information for Vermont Prescribers of Prescription Drugs

Information for Vermont Prescribers of Prescription Drugs Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same

More information

P&T Committee Meeting Minutes GHP Family November 20, 2018

P&T Committee Meeting Minutes GHP Family November 20, 2018 P&T Committee Meeting Minutes GHP Family November 20, 2018 Present: Bret Yarczower, MD, MBA Chair Kristen Bender, PharmD via phone Rajneel Chohan Pharm.D. Alyssa Cilia, RPh via phone Kimberly Clark, PharmD

More information

Regence MedAdvantage + Rx Classic (PPO) 2016 Formulary. (List of Covered Drugs)

Regence MedAdvantage + Rx Classic (PPO) 2016 Formulary. (List of Covered Drugs) Regence MedAdvantage + Rx Classic (PPO) 2016 Formulary (List of Covered s) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission

More information

Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND

Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND Therapeutic Strategies for Pain and Disability Pharmacotherapy Rehabilitative approaches

More information

FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes

FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes Safety Announcement [7-9-2015] The U.S. Food and Drug Administration (FDA) is strengthening

More information

Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY. Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition.

Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY. Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition. Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition. 30- day 90- day 30- day 90- day quantity quantity quantity quantity

More information

Self Report Seizure Survey Summary 2017

Self Report Seizure Survey Summary 2017 Self Report Seizure Survey Summary 2017 Tetrasomy 18p 61 responses 33 had at least one seizure = 54% 8 had a seizure in the last year Valproate (Depakote) 7 Valproate (Depakote, Epilium) 2 Lamotrigene

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

Commonwealth Care Alliance (Medicare-Medicaid Plan) One Care Plan

Commonwealth Care Alliance (Medicare-Medicaid Plan) One Care Plan 2018 List of Covered Drugs (Formulary) Commonwealth Care Alliance (Medicare-Medicaid Plan) One Care Plan 30 Winter Street Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS

More information

Trusted Health Plan Formulary

Trusted Health Plan Formulary 2018 Trusted Health Plan Formulary Version 19; Effective 10/22/18 Introduction... 6 The Trusted Health Plan Pharmacy and Therapeutics Committee (P&T)... 6 Notice...6 Preface...6 Product Selection Criteria...

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

Month/Year of Review: January 2012 Date of Last Review: February 2007

Month/Year of Review: January 2012 Date of Last Review: February 2007 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)

More information

Drug Class Preferred Agents Non-Preferred Agents

Drug Class Preferred Agents Non-Preferred Agents Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner of the Department for

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA

More information

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine

More information

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1. ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882

More information

Step Therapy Requirements

Step Therapy Requirements Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet

More information

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine

More information

2019 Formulary Update

2019 Formulary Update MEDICARE ADVANTAGE BlueShield of Northeastern New York Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January. This document

More information

HNE Medicare Advantage Plan (HMO and HMO- POS) 2016 Formulary (List of Covered Drugs)

HNE Medicare Advantage Plan (HMO and HMO- POS) 2016 Formulary (List of Covered Drugs) HNE Medicare Advantage Plan (HMO and HMO- POS) 2016 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION

More information

TennCare Program TN MAC Price Change List As of: 03/30/2017

TennCare Program TN MAC Price Change List As of: 03/30/2017 1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017

More information

Triptan Quantity Limit

Triptan Quantity Limit *- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

Rheumatoid Arthritis

Rheumatoid Arthritis Rheumatoid Arthritis Rheumatoid Arthritis (RA) is a form of arthritis characterized by swelling and pain in the joints. If severe enough RA can also affect people s internal organs. RA is considered an

More information

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more NSAID steroid update Leo Semes, OD, FAAO I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more II. Topical NSAIDS ophthalmic application III. Oral NSAIDs a. Precautions

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA

More information

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 02.19

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 02.19 Clinical Policy: Reference Number: CP.PST.01 Effective Date: 12.28.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information